SHANGHAI, March 22, 2022 (GLOBE NEWSWIRE) — Wision A.I. Ltd, a startup in the field of artificial intelligence assisted diagnostics for optical medical imaging, today announced the expansion of its product portfolio with recent U.S. Food & Drug Administration (FDA) 510(k) Clearance for EndoScreener, its AI-assisted polyp detection software during colonoscopy, and an FDA presubmission in queue for an upcoming histopathology AI software that assists in the localization of high-grade dysplasia (HGD) in whole slide imaging (WSI).
Trending
- OneOncology and OpenEvidence Partner to Improve Cancer Care Nationwide (OneOncology)
- FIT-Based Screening Linked to Drop in Colorectal Cancer Mortality (Medpage Today)
- Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data (Business Wire)
- The physician opportunity cost nobody puts on a bill (KevinMD)
- A ‘molecular switch’ that heals the gut—and that colorectal cancer hijacks to spread (Medical Xpress)
- Why gastroenterology is especially exposed to predatory contracts, GI says (Becker’s GI & Endoscopy)
- The Microbiome Is Not a Bar Code
- Not All False-Positive Stool DNA Tests Should be Dismissed (GI & Endoscopy News)
